TY - JOUR
T1 - Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
AU - Gerber, Marisa T.
AU - Mondy, Kristin E.
AU - Yarasheski, Kevin E.
AU - Drechsler, Henning
AU - Claxton, Sherry
AU - Stoneman, John
AU - DeMarco, Debra
AU - Powderly, William G.
AU - Tebas, Pablo
N1 - Funding Information:
Financial support. This study was supported in part by the Washington University General Clinical Research Center (grants AI 25903, AI 32783 DK 59532, and RR00036) and the Campbell Foundation. P.T. is a recipient of the Glaxo SmithKline Development Partners Junior Faculty Award. K.E.M. was supported by the National Institute of Allergy and Infectious Diseases (training grant 5T32-AI 07172). K.E.Y. and S.C. were supported by the National Institutes of Health (grants DK-49393, DK-54163 and DK-59531).
PY - 2004/8/1
Y1 - 2004/8/1
N2 - Background. Extended release (ER)-niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)-seronegative individuals, has not been evaluated in the HIV-infected population. Methods. This open, prospective trial evaluated the safety and efficacy of ER-niacin therapy for antiretroviral therapy-associated dyslipidemia. Fourteen individuals received ER-niacin at maximum doses of 2000 mg per day for 14 weeks. Results. Significant reductions in serum levels of triglycerides (P = .02), total cholesterol (P = .005), and non-HDL cholesterol (P = .04) were seen after ER-niacin therapy. Seven of 11 subjects were glucose intolerant after ER-niacin therapy; for 3 of these subjects, this was a new finding. β-Cell sensitivity to basal glucose levels increased significantly without concomitant increase in overall glucose disposition indices. The values for the homeostasis model of insulin resistance index increased significantly (P = .005). Conclusion. ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option.
AB - Background. Extended release (ER)-niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)-seronegative individuals, has not been evaluated in the HIV-infected population. Methods. This open, prospective trial evaluated the safety and efficacy of ER-niacin therapy for antiretroviral therapy-associated dyslipidemia. Fourteen individuals received ER-niacin at maximum doses of 2000 mg per day for 14 weeks. Results. Significant reductions in serum levels of triglycerides (P = .02), total cholesterol (P = .005), and non-HDL cholesterol (P = .04) were seen after ER-niacin therapy. Seven of 11 subjects were glucose intolerant after ER-niacin therapy; for 3 of these subjects, this was a new finding. β-Cell sensitivity to basal glucose levels increased significantly without concomitant increase in overall glucose disposition indices. The values for the homeostasis model of insulin resistance index increased significantly (P = .005). Conclusion. ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option.
UR - http://www.scopus.com/inward/record.url?scp=3943052088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3943052088&partnerID=8YFLogxK
U2 - 10.1086/422144
DO - 10.1086/422144
M3 - Article
C2 - 15307011
AN - SCOPUS:3943052088
SN - 1058-4838
VL - 39
SP - 419
EP - 425
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -